Dec 16 (Reuters) - Acasti Pharma Inc APO.V :
* Provides update on capre development pathway
* Says received positive feedback from the US food and drug administration
(FDA) on the proposed development pathway for capre
* Acasti is pursuing pivotal bioavailability bridging study, comparing capre
and another FDA-approved omega-3 prescription drug
* Source text for Eikon ID:nGNXMIWMBa
* Further company coverage APO.V